HEPION PHARMACEUTICALS, INC. Asset Impairment Charges
HEPION PHARMACEUTICALS, INC. (HEPA) reported Asset Impairment Charges of $402.75 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AssetImpairmentCharges · last filed 2026-08-13
- HEPION PHARMACEUTICALS, INC. asset impairment charges for the quarter ending 2025-12-31 was $0.00.
- HEPION PHARMACEUTICALS, INC. asset impairment charges for the quarter ending 2025-09-30 was $0.00.
- HEPION PHARMACEUTICALS, INC. asset impairment charges for the quarter ending 2025-06-30 was $402.75K.
- HEPION PHARMACEUTICALS, INC. asset impairment charges for the quarter ending 2025-03-31 was $0.00.
- HEPION PHARMACEUTICALS, INC. asset impairment charges for fiscal 2025 was $402.75K.
| Period end | Asset Impairment Charges 3 month | Asset Impairment Charges 6 month | Asset Impairment Charges 9 month | Asset Impairment Charges 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $402.75K derived: sum of 3 quarters · filed 2026-03-12 | $402.75K 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $402.75K derived: sum of 2 quarters · filed 2025-11-12 | $402.75K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $402.75K 10-Q · filed 2025-08-14 | $402.75K 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |